Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.06% |
| Dec 31, 2025 | -80.60% |
| Sep 30, 2025 | -42.12% |
| Jun 30, 2025 | -38.68% |
| Mar 31, 2025 | -128.79% |
| Dec 31, 2024 | -25.81% |
| Sep 30, 2024 | -15.47% |
| Jun 30, 2024 | -19.06% |
| Mar 31, 2024 | -46.74% |
| Dec 31, 2023 | -17.40% |
| Sep 30, 2023 | -54.68% |
| Jun 30, 2023 | -20.20% |
| Mar 31, 2023 | 1.04% |
| Dec 31, 2022 | 41.80% |
| Sep 30, 2022 | 22.13% |
| Jun 30, 2022 | 29.83% |
| Mar 31, 2022 | 3.40% |
| Dec 31, 2021 | 74.45% |
| Sep 30, 2021 | 82.19% |
| Jun 30, 2021 | 32.54% |
| Mar 31, 2021 | 21.98% |
| Dec 31, 2020 | 20.60% |
| Sep 30, 2020 | 21.27% |
| Jun 30, 2020 | 29.14% |
| Mar 31, 2020 | 15.41% |
| Dec 31, 2019 | -42.89% |
| Sep 30, 2019 | 134.79% |
| Jun 30, 2019 | 20.44% |
| Mar 31, 2019 | 52.95% |
| Dec 31, 2018 | 27.44% |
| Sep 30, 2018 | 27.21% |
| Jun 30, 2018 | 27.45% |
| Mar 31, 2018 | 21.78% |
| Dec 31, 2017 | -15.89% |
| Sep 30, 2017 | 3.10% |
| Jun 30, 2017 | 28.14% |
| Mar 31, 2017 | 0.81% |
| Dec 31, 2016 | 38.15% |
| Sep 30, 2016 | 32.52% |
| Jun 30, 2016 | -28.06% |
| Mar 31, 2016 | -147.50% |
| Dec 31, 2015 | -48.97% |
| Sep 30, 2015 | -37.95% |
| Jun 30, 2015 | -44.33% |